Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

New horizons in breast cancer: the promise of immunotherapy.

de la Cruz-Merino L, Palazón-Carrión N, Henao-Carrasco F, Nogales-Fernández E, Álamo-de la Gala M, Vallejo-Benítez A, Chiesa M, Sánchez-Margalet V; GEICAM (Spanish Breast Cancer Research Group) and GÉTICA (Spanish Group for Cancer Immuno-Biotherapy).

Clin Transl Oncol. 2018 Jun 18. doi: 10.1007/s12094-018-1907-3. [Epub ahead of print] Review.

PMID:
29916188
2.

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.

Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators.

Ann Oncol. 2018 Aug 1;29(8):1763-1770. doi: 10.1093/annonc/mdy201.

3.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G.

J Clin Oncol. 2018 Aug 20;36(24):2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3.

PMID:
29860922
4.

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.

Losa F, Iglesias L, Pané M, Sanz J, Nieto B, Fusté V, de la Cruz-Merino L, Concha Á, Balañá C, Matías-Guiu X.

Clin Transl Oncol. 2018 May 28. doi: 10.1007/s12094-018-1899-z. [Epub ahead of print] Review.

PMID:
29808414
5.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.

J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.

6.

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A.

Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13.

7.

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.

de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B.

J Transl Med. 2017 Jun 24;15(1):146. doi: 10.1186/s12967-017-1246-0.

8.

Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.

Provencio M, Royuela A, Torrente M, Pollán M, Gómez-Codina J, Sabín P, Llanos M, Gumá J, Quero C, Blasco A, Aguiar D, García-Arroyo FR, Lavernia J, Martínez N, Morales M, Saenz-Cusi Á, Rodríguez D, Calvo V, de la Cruz-Merino L, de la Cruz MÁ, Rueda A; Spanish Lymphoma Oncology Group.

Cancer. 2017 Oct 1;123(19):3709-3716. doi: 10.1002/cncr.30795. Epub 2017 Jun 13.

PMID:
28608996
9.

Advances in the Immunobiological Therapies for Advanced Melanoma.

Pérez Gago MC, Saavedra Santa Gadea O, de la Cruz-Merino L.

Actas Dermosifiliogr. 2017 Oct;108(8):721-728. doi: 10.1016/j.ad.2017.01.016. Epub 2017 Apr 25. Review. English, Spanish.

PMID:
28388991
10.

Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives.

de la Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco FH, Sánchez-Margalet V.

Int Rev Cell Mol Biol. 2017;331:1-53. doi: 10.1016/bs.ircmb.2016.09.008. Epub 2016 Dec 2. Review.

PMID:
28325210
11.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C.

Eur J Cancer. 2017 Apr;75:313-322. doi: 10.1016/j.ejca.2017.01.012. Epub 2017 Mar 4.

PMID:
28264791
12.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J.

Lancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30.

PMID:
27480103
13.

Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience.

Arance AM, Berrocal A, Lopez-Martin JA, de la Cruz-Merino L, Soriano V, Martín Algarra S, Alonso L, Cerezuela P, La Orden B, Espinosa E.

Clin Transl Oncol. 2016 Nov;18(11):1147-1157. Epub 2016 Mar 17.

PMID:
26983408
14.

[Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].

Romero Carreño E, Marcos Rodríguez JA, Santana Martínez S, de la Cruz Merino L.

Farm Hosp. 2016 Mar 1;40(2):134-6. doi: 10.7399/fh.2016.40.2.9360. Spanish. No abstract available.

15.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S.

Melanoma Res. 2016 Jun;26(3):278-83. doi: 10.1097/CMR.0000000000000254.

16.

Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach.

Martín-Algarra S, de la Cruz-Merino L, Soriano V, Manzano JL, Espinosa E.

Clin Transl Oncol. 2016 Oct;18(10):1044-50. doi: 10.1007/s12094-016-1484-2. Epub 2016 Jan 22.

PMID:
26801342
17.

SEOM clinical guidelines in metastatic breast cancer 2015.

Gavilá J, Lopez-Tarruella S, Saura C, Muñoz M, Oliveira M, De la Cruz-Merino L, Morales S, Alvarez I, Virizuela JA, Martin M.

Clin Transl Oncol. 2015 Dec;17(12):946-55. doi: 10.1007/s12094-015-1476-7. Epub 2015 Dec 18.

18.

SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma.

Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, Gumá I Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Rueda Domínguez A.

Clin Transl Oncol. 2015 Dec;17(12):1014-9. doi: 10.1007/s12094-015-1437-1. Epub 2015 Nov 19.

19.

SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.

Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, Gumá I Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Provencio Pulla M.

Clin Transl Oncol. 2015 Dec;17(12):1005-13. doi: 10.1007/s12094-015-1429-1. Epub 2015 Oct 26.

20.

Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.

Antolín-Novoa S, Blanco-Campanario E, Antón A, Gallegos-Sancho MI, Pérez-Carrión R, Peláez I, Galán-Brotons A, de la Cruz-Merino L, Murías-Rosales A; SmallHER Study Group.

Clin Transl Oncol. 2015 Nov;17(11):862-9. doi: 10.1007/s12094-015-1316-9. Epub 2015 Jun 24.

PMID:
26103952

Supplemental Content

Loading ...
Support Center